How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) released its quarterly earnings data on Wednesday, August, 14th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of ($0.18) by $1.30. The business had revenue of $21.79 million for the quarter.

When did Fibrocell Science's stock split?

Shares of Fibrocell Science reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Fibrocell Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG) , Celldex Therapeutics (CLDX) , Neos Therapeutics (NEOS) , Amarin (AMRN) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Neurotrope (NTRP) , Verastem (VSTM) , Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX) .

NASDAQ:FCSC

Fibrocell Science (FCSC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free FCSC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $3.00
▼
$3.00
50-Day Range: $3.00
▼
$3.00
52-Week Range: $1.45
▼
$3.28

Volume: N/A
Average Volume: 78,673 shs
Market Capitalization: $29.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Fibrocell Science alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Fibrocell Science Stock (NASDAQ:FCSC)

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

FCSC Stock News Headlines

February 20, 2024 | forbes.com

Best Data Science Bootcamps Online In 2024

February 6, 2024 | dailymail.co.uk

Science & Tech News

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 16, 2023 | usnews.com

What You Need to Know About Becoming a Computer Science Major

April 7, 2023 | marketwatch.com

Epidermolysis Bullosa Therapeutics Market Factual Overview Research Report 2023-2030

January 13, 2023 | forbes.com

Oramed Pharmaceuticals

December 27, 2022 | thestreet.com

Fibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment Designation

See More Headlines

Receive FCSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FCSC
CUSIP: N/A
CIK: 357097
Web: fibrocell.com
Phone: 484-713-6000
Fax: N/A
Employees: 19
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 30.00
P/E Growth: N/A
Net Income: $-10,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: 23.10%
Return on Assets: 10.56%

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 5.09
Quick Ratio: 5.09

Sales & Book Value

Annual Sales: $350,000.00
Price / Sales: 83.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.98 per share
Price / Book: 3.06

Miscellaneous

Outstanding Shares: 9,760,000
Free Float: N/A
Market Cap: $29.28 million
Optionable: Optionable
Beta: 1.67

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. John Michael Maslowski (Age 44)
Pres, CEO & Director
Mr. Sean D. Buckley (Age 37)
VP of Bus. Admin. & Corp. Sec.
Mr. Robert G. Partridge
VP of Global Marketing, Communications and Investor Relations
Ms. Michele Mchugh-Mazzatta
VP of Sales
Dr. Pierre Compte
Managing Director of Switzerland

Key Competitors

View All Competitors

FCSC Stock Analysis - Frequently Asked Questions

How were Fibrocell Science's earnings last quarter?: Fibrocell Science Inc (NASDAQ:FCSC) released its quarterly earnings data on Wednesday, August, 14th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of ($0.18) by $1.30. The business had revenue of $21.79 million for the quarter.
When did Fibrocell Science's stock split?: Shares of Fibrocell Science reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of Fibrocell Science own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Neurotrope (NTRP), Verastem (VSTM), Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX).

This page (NASDAQ:FCSC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fibrocell Science (FCSC) Stock Price, News & Analysis

About Fibrocell Science Stock (NASDAQ:FCSC)

FCSC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

FCSC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info